Clinical course of acute coronary syndrome under different pharmacological treatment strategies
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
Abstract
Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality worldwide. The clinical course of ACS can vary significantly depending on the applied pharmacological treatment strategy. This study aims to evaluate and compare the effectiveness of different medication-based approaches in the management of ACS and their influence on clinical outcomes. A cohort of patients diagnosed with ACS was monitored and stratified according to the therapeutic regimens received, including antiplatelet therapy, anticoagulants, beta-blockers, statins, and other cardioprotective agents. Key clinical parameters such as recurrence of ischemic events, incidence of complications, and in-hospital mortality were analyzed. The results indicate that personalized selection and timely initiation of optimal pharmacotherapy significantly improve prognosis and reduce adverse cardiovascular events. These findings emphasize the importance of individualized therapeutic strategies in the management of ACS to achieve better clinical outcomes.
Article Details
References
Carvalho PEP, Gewehr DM, Nascimento BR, Melo L, Burkhardt G, Rivera A, Braga MAP, Guimarães PO, Mehran R, Windecker S, Valgimigli M, Angiolillo DJ, Bhatt DL, Sandoval Y, Chen SL, Stone GW, Lopes RD. Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. JAMA Cardiol. 2024 Dec 1;9(12):1094-1105. doi: 10.1001/jamacardio.2024.3216. PMID: 39382876; PMCID: PMC11581547. DOI: https://doi.org/10.1001/jamacardio.2024.3216
Byrne RA, Rossello X, Coughlan JJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 DOI: https://doi.org/10.1093/eurheartj/ehad191
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(3): e4-e17. doi:10.1161/CIR.0000000000001039 DOI: https://doi.org/10.1161/CIR.0000000000001061
Mauri L, Kereiakes DJ, Yeh RW, et al.; DAPT Study Investigators twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166. doi:10.1056/NEJMoa1409312 DOI: https://doi.org/10.1056/NEJMoa1409312
Rodriguez F, Harrington RA. Management of antithrombotic therapy after acute coronary syndromes. N Engl J Med. 2021;384(5):452-460. doi:10.1056/NEJMra1607714 DOI: https://doi.org/10.1056/NEJMra1607714
Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022;19(2):117-132. doi:10.1038/s41569-021-00598-1 DOI: https://doi.org/10.1038/s41569-021-00598-1
Efthimiou O, Debray TPA, van Valkenhoef G, et al.; GetReal Methods Review Group. GetReal in network meta-analysis: a review of the methodology. Res Synth Methods. 2016;7(3):236-263. doi:10.1002/jrsm.1195 DOI: https://doi.org/10.1002/jrsm.1195
Khan SU, Singh M, Valavoor S, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation. 2020;142(15):1425-1436. doi:10.1161/CIRCULATIONAHA.120.046308 DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046308
Kuno T, Ueyama H, Takagi H, Fox J, Bangalore S. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: insights from a network meta-analysis of randomized trials. Cardiovasc Revasc Med. 2021; 28:50-56. doi: 10.1016/j.carrev.2020.07.039 DOI: https://doi.org/10.1016/j.carrev.2020.07.039
Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022). Cochrane; 2022.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71):n71. doi:10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
Moras E, Zaid S, Gandhi K, Barman N, Birnbaum Y, Virani SS, Tamis-Holland J, Jneid H, Krittanawong C. Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population. Curr Atheroscler Rep. 2024 Jul;26(7):231-248. doi: 10.1007/s11883-024-01203-9. Epub 2024 May 9. PMID: 38722473. DOI: https://doi.org/10.1007/s11883-024-01203-9